Pharma Focus Asia
KP - Sustainable Packaging Solutions

AbbVie Invests US$223 million to Expand Biologics Manufacturing Site in Singapore


AbbVie invests US$223 million to expand biologics manufacturing capacity in Singapore.


This new investment will increase an additional 24,000 litres of biologics drug-substance capacity to manufacturing network. This expansion is poised to bolster existing product lines and provide essential support for upcoming immunology and oncology compounds within the pipeline.

The expansion will enhance global manufacturing capabilities, facilitating the growth of biologics pipeline. This investment underscores dedication to meeting patient commitments both now and in the future.

After completion, the new expansion will increase the biologics manufacturing capacity within the global network and create over 100 new job opportunities in Singapore. 

Once fully operational, the expanded manufacturing facility will employ over 500 individuals across various roles including manufacturing, quality assurance, supply chain, engineering, and administration.

Construction for the expansion is slated to commence later this year, with operations anticipated to begin in 2026.


Name        AbbVie
Type         Expansion
Budget   US$223 million
Year          2026

Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelTFS - ODW - The Technology Debate: Single-Use vs. Stainless SteelAsia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 20244th Middle East Pharmacoeconomics and Drug Policy Summit 2024Digital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference
Searching for an end-to-end patient tech solution?